Capsugel links with Pulmatrix to develop novel inhaled therapeutics

USA-based privately-held Capsugel and Pulmatrix (Nasdaq: PULM) have formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases.

The agreement provides Capsugel with exclusive rights to manufacture clinical trial and commercial batches of iSPERSE-based inhaled therapeutic candidates being developed by Pulmatrix and its potential development partners. Capsugel will combine its spray drying process development, scale-up expertise and commercial manufacturing capabilities at its Bend Research facility in Bend, Ore. with Pulmatrix' iSPERSE (inhaled small particles easily respirable and emitted) technology. Financial terms were not disclosed.

"This strategic partnership with Pulmatrix puts our companies at the forefront of bringing unique inhalation products to the market to deliver better patient outcomes," said Dan Dobry, head of alliance strategy at Bend Research, a division of Capsugel Dosage Form Solutions. "We look forward to working with Pulmatrix to help advance its pipeline of proprietary and partnered products utilizing our spray dry technology and infrastructure, and to jointly explore opportunities to collaborate with the broader pharmaceutical industry to develop next-generation inhalation therapies," he added.